Pyrrolo[2,3-d]pyrimidine compounds

Details Pyrrolo[2,3-d]pyrimidine compounds Pyrrolo[2,3-d]pyrimidine compounds

2007-07-27

2009-10-13

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S280000

Reexamination Certificate

active

07601727

ABSTRACT:
A compound of the formulawherein R1, R2and R3are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

REFERENCES:
patent: 3037980 (1962-06-01), Hitchings, et al.
patent: 5389509 (1995-02-01), Maskasky
patent: 5496946 (1996-03-01), Akimoto et al.
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6080747 (2000-06-01), Uckun et al.
patent: 6136595 (2000-10-01), Ihle et al.
patent: 6180636 (2001-01-01), Traxler et al.
patent: 6187552 (2001-02-01), Roberds et al.
patent: 6310063 (2001-10-01), Ge et al.
patent: 6610847 (2003-08-01), Blumenkopf et al.
patent: 6627754 (2003-09-01), Blumenkopf et al.
patent: 6635762 (2003-10-01), Blumenkopf et al.
patent: 6696567 (2004-02-01), Blumenkopf et al.
patent: 6890929 (2005-05-01), Blumenkopf et al.
patent: 6956041 (2005-10-01), Blumenkopf et al.
patent: 6962993 (2005-11-01), Blumenkopf et al.
patent: 6965027 (2005-11-01), Flanagan et al.
patent: 7079208 (2006-07-01), Kim et al.
patent: 2003/0073719 (2003-04-01), Flanagan
patent: 2004/0058922 (2004-03-01), Blumenkopf et al.
patent: 2004/0229923 (2004-11-01), Wilcox
patent: 2005/0159434 (2005-07-01), Flanagan
patent: 2005/0171128 (2005-08-01), Blumenkopf
patent: 2005/0197349 (2005-09-01), Blumenkopf
patent: 0334636 (1989-09-01), None
patent: 0795556 (1997-09-01), None
patent: 0682027 (1997-10-01), None
patent: 0915303 (1963-01-01), None
patent: 09519774 (1995-07-01), None
patent: 9802438 (1996-07-01), None
patent: 09640142 (1996-12-01), None
patent: 9702262 (1997-01-01), None
patent: 9702266 (1997-01-01), None
patent: 9713771 (1997-04-01), None
patent: 9718212 (1997-05-01), None
patent: 9727199 (1997-07-01), None
patent: 9728161 (1997-08-01), None
patent: 9732879 (1997-09-01), None
patent: 9749706 (1997-12-01), None
patent: 9802437 (1998-01-01), None
patent: 9807726 (1998-02-01), None
patent: 9823613 (1998-06-01), None
patent: 9833798 (1998-08-01), None
patent: 9951599 (1999-10-01), None
patent: 9961428 (1999-12-01), None
patent: 9965908 (1999-12-01), None
patent: 9965909 (1999-12-01), None
patent: 0000202 (2000-01-01), None
patent: 0010981 (2000-03-01), None
patent: 0017203 (2000-03-01), None
patent: 0142246 (2001-06-01), None
patent: 0200661 (2002-01-01), None
Shouda et al., The Journal of Clinical Investigation 108(12): 1781-1788, 1998.
Aringer et al., Life Sciences 64(24): 2173-2186, 1999.
Traxler et al. Ex. Opin. Ther. Patents 7(6): 571-588, 1997.
U.S. Appl. No. 09/335,121, filed Jun. 17, 1999, Blumenkopf et al.
Baird, et al., T Cell Development and Activation in JAK-3-Deficient Mice, J Leukocyte Biology 1998 V63 p. 669-672.
Candotti, et al., “Severe combined Immune Deficiencies due to Defects in the Common y chain-JAK3 Signaling Pathway” 1998 Springer Semin. Immunopathology, V19 p. 401-15.
Chen, et al., “Advantage in Cytokine signaling:the role of JAKs and STATs”, Transplantation Proceedings 1999 V31 p. 1482-87.
Eynon, et al., “Disruptionof Cytokine signaling in Lyphoid Development:Unique Contributions of the Common Cytokine gamma Chain . . . ”, J of Inter. Cytokine Res. 1996 V16 p. 667-84.
Ghosh, et al., “4-[(3-Bromo-4-hydroxphenyl)amino]6,7-dimethoxyquinazolin-1-ium chloride Methanol Solvate . . . ”2001 Acto Crystallogr, C:Crystal, Structure Commun. V C57 p. 76-78.
Hanke, et al., “Role of Tyrosine Kiniases in Lymphocyte Activation: Targets for Drug Intervention”, Inflammation Research 1995 V44 p. 357-71.
Ihle, et al.,“The Janus Protein Tyrosine Kinase Family and its Role in Cytokine Signaling” Advance Immunology 1995 V60 p. 1-35.
Ihle, et al.,“Th Janus Protein Tyrosine Kinases in Hematopoietic Cytokine Signaling” Semin Immunology 1995 V7 p. 247.
Kirken, et al., “Activation of JAK# but not JAK1 is Critical for IL-2-Induced Proliferation and Stat 5 Recruitment by a Cooh-Terminal Region of IL-2 . . . ”Cytokine V7 p. 689-00 1995.
Liu, et al.,“JAK/STAT Signalingby Cytokine Receptors” Current Opinion of Immunology 1998 V10 p. 271-78.
Li, et al.,“Blocking the Common y-Chain of Cytokine receptors Induces T CellApoptosis and Long-term Islet Allograft Survival” J of Immunology V164 p. 1193-99 2000.
Leonard, et al., “JAKS and STATS:Biological Implications” 1998 Annual Review of Immunology V16 p. 293-322.
Malaviya, et al., “Treatmentof Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with . . . ”J Pharma. and Exp Ther. 2000 V295 pa 912-26.
Malaviya, et al., “Genetic and Biochemical Evidence for a Critical Role of Janus Kinase(JAK)-3....”Biochem. and Biophys. res. Comm. 1999 V257 p. 807-13.
Malaviya, et al., “Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis”, J Bio. Chemistry 1999 V274 p. 27028-38.
Malabarba, et al.,“Activation JAK3 but not JAK1, is critical to interleukin-4(IL4) Stimulated Proliferation and Requires a . . . ”J of Biol. Chem. 1995 V270 p. 9630-9637.
Moriggi, et al., “Stat5 Activation is Uniquely Associated with Cytokine signaling in Peripheral T Cells” Immunity 1995 V11 p. 225-230.
Musso, et al., “Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukins 2,4,and 7” J of Exp. Med. 1995 vol. 181 p. 1425-31.
Nelson, et al., “Requirement for an Initial signal from the Membrane Proximal Region of the Interleukin 2 Receptor . . . ”Proceedings of Nat. Academy of Sci. 1997 V94 p. 1878-83.
Notarangelo, et al., “Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase” Progressive Immunodeficiency 1996 V6 p. 61-68.
Oakes, et al.,“Signaling via IL-2 and IL-4 in JAK3-Deficient Severe Combined Immunodeficiency ymphocytes:JAK3-Dependent and Independent Pathways” Immunity 1996 v5 p. 605-15.
Oshea, et al., “Phosphorylation and Activation of the JAK3 Janus Kinase in response to Interleukin-2”, Nature 1994 V370 p. 151-53.
Russell, et al., “Interaction of IL-2RB and y chains with JAK1 and JAK3: Implications for XSCID and XCID” Science 1994 V266 pp. 1042-1045.
Sudbeck, et al. “Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukernic Agents” Clin. Cancer Res. 1999 V5 p. 1569-1582.
Sudbeck, et al. “Recent Advances in JAK3 Kinase Inhibitors” !Drugs V2 p. 1026-1030 1999.
Sudbeck, et al. “An Inhibitor of Janus Kinase 3:4-(4-hydroxphenynlamino)-6,7 . . . ” Crystal Structure Communications 2000 V. C56 p. 1282-83.
Thomis, et al. “The JAK family Tyrosine Kinase JAK3 is Required for IL-2 Synthesis by Naive/resting CD4” J of Immunology 1999 V 163 p. 5411-5417.
Thomis, et al., “Peripheral Expression of JAK3 is Required to Maintain T Lymphocate Function” J of Experimental Medicine 1997 V 185 p. 197-206.
Traxler, et al., “Protein Tyrosine Kinase Inhibitors in Cancer Treatment” Expert Opinion in Therapeutic Patents V7 p. 571-588 1997.
Traxler, et al., “4-(Phenylamino)pyrrolopyrimidines: patent and Selective ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine . . . ” J Med. Chem 1996 V 39 2285-92.
Trieu, et al., “A Specific Inhibitor of Janus Kinase-3 Increases survival in a Trasgenic Mouse Model of Amyotrophic . . . ” Bioch. And Biophys. Res Comm. 2000 V267 p. 22-25.
Uckun, et al., “In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [4-(4-Hydroypheny1) . . . ”Clinical Cancer Res. 1999 V5 p. 2954-62.
Wang, et al., “JAK3 Stat and MAPK Signal

Affiliated with

Also associated with

Rating

Pyrrolo[2,3-d]pyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo[2,3-d]pyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[2,3-d]pyrimidine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4063426